Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2007; 13(12): 1820-1823
Published online Mar 28, 2007. doi: 10.3748/wjg.v13.i12.1820
Published online Mar 28, 2007. doi: 10.3748/wjg.v13.i12.1820
Table 1 Indications for colonoscopy in two groups of patients n = 200
Indication | Group 1(active drug) | Group 2(placebo) | Total |
Unexplained abdominal pain | 55 | 56 | 111 |
Suspected colonic tuberculosis | 14 | 12 | 26 |
Ulcerative colitis | 11 | 13 | 24 |
Hematochezia | 5 | 5 | 10 |
Fecal occult blood positive | 4 | 6 | 10 |
Colon cancer | 2 | 4 | 6 |
Occult gastrointestinal bleeding | 2 | 2 | 4 |
Colonic polyp | 1 | 2 | 3 |
Portal hypertension (colonic bleed) | 2 | 1 | 3 |
Crohn’s disease | 2 | 1 | 3 |
Table 2 Effect of hyoscine N-butyl bromide on the vital parameters mean ± SD
Drug | Placebo | P | |
Pulse rate before administration | 85.7 (4.7) | 85.6 (3.8) | NS |
Pulse rate after procedure | 93.2 (4.9) | 86.5 (3.9) | < 0.001 |
Highest pulse rate achieved | |||
before ileoscopy | 94 | 92 | |
Highest pulse rate achieved | |||
during ileoscopy | 102 | 92 | |
Po2 before administration | 95.4 (1.5) | 95 (1.3) | NS |
Po2 after administration | 94.4 (1.8) | 94.6 (1.7) | NS |
Minimum Po2 before ileoscopy | 92 | 94 | NS |
Minimum Po2 during ileoscopy | 90 | 90 | NS |
- Citation: Misra S, Dwivedi M. Role of intravenously administered hyoscine butyl bromide in retrograde terminal ileoscopy: A randomized, double-blinded, placebo-controlled trial. World J Gastroenterol 2007; 13(12): 1820-1823
- URL: https://www.wjgnet.com/1007-9327/full/v13/i12/1820.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i12.1820